Sodium Valproate

Bob Blackman Excerpts

Thursday 29th October 2026 Commons Chamber

[Cat Smith (Lancaster and Wyre) (Lab)]

It is not the first time that I have had an Adjournment debate on sodium valproate in my 11-and-a-bit years as a Member of Parliament. It continues to be an issue that affects so many, and for which justice still feels so far away.

Given the history of this House debating the topic, I do not intend to spend much time going over the history of the drug, which has been used to treat epilepsy and bipolar disorder since the early 1970s. For the benefit of anyone who is tuning in for the first time, I will go over the brief facts of what happened. The drug is teratogenic and was known to be teratogenic from the time it was first licensed. Despite that, doctors were initially advised that the risk did not justify

“discouraging a woman who needs anticonvulsant treatment from having a child or changing a satisfactory drug regimen when the epilepsy is well controlled.”

The result has been that we have been playing catch-up ever since, with the Valproate Pregnancy Prevention Programme only being launched in 2018, following tireless campaigning from women affected, such as my constituent Janet Williams—who is in the Public Gallery—and her friend and colleague Emma Murphy.

It is difficult to calculate the number of children exposed to valproate in utero since its 1973 licensing. The Patient Safety Commissioner has made an estimate of around 14,000 for the period from 1972 to 2017 in England. Diagnosis often gets picked up when clinicians, or in some cases parents, recognise facial dysmorphic features. Children born with foetal valproate spectrum disorder can have a wide range of physical and mental health symptoms, including but not limited to weak muscles, visual problems, hearing difficulties, difficulties with balance, social anxiety, low energy, heightened sensitivity to noise and difficulties in regulating emotions. One of the biggest health conditions facing people with foetal valproate spectrum disorder is autism. A significant number also have attention deficit hyperactivity disorder, or ADHD, dyspraxia, sensory processing disorder and epilepsy.

It can affect children in very different ways. In some of the most severe cases—I know that the hon. Member for Harrow East (Bob Blackman) has a constituent who is very severely affected—the individual can end up bedbound and very severely disabled. For some children, autism and sensory processing may be more of an issue.

[Bob Blackman (Harrow East) (Con)]

I thank the hon. Member for introducing this long-awaited debate. I have a constituent, Karen Buck, whose daughter, Bridget Doyle, was born paralysed, is bedbound and suffers from autism. The reality is that there are many victims out there who suffer from a variety of conditions, as the hon. Lady quite rightly points out—not least spina bifida, which she has not mentioned. The problem here is that legal aid for the court case, which was established to try to get recompense for those victims, was withdrawn some 20 years ago. Unfortunately, although commitments have been made time and again to help these people, these mothers are now advanced in age, and the children they have supported will desperately need support when their lives end. Does the hon. Lady think there is now a need for a proper compensation scheme?

--- Later in debate ---

[Dame Diana Johnson]

I am very happy to discuss that with my hon. Friend and see what we can do.

I want to deal with non-financial redress. It is important to recognise that people need support now. The Department is working with the NHS to put in place a range of measures to support the women and their families, alongside action to strengthen the safe prescribing of sodium valproate. In February, on the second anniversary of the Hughes report, the Minister for Secondary Care, my hon. Friend the Member for Bristol South (Karin Smyth), set out how the Department is addressing their needs by improving the clinical services and treatment that patients receive, commissioning further research and initiating long-term preventive measures. I would like to update colleagues on those initiatives.

First, on the improvements to services and treatment, the number of women who have been prescribed sodium valproate has gone down since 2018, although there is a cohort who have already been affected and require specific treatment. We must ensure that our healthcare system is shaped around their needs and experiences. Shortly after the Government came to office, NHS England began operating the foetal exposure to medicines pilot service in hospitals in Manchester and Newcastle, to which my hon. Friend the Member for Lancaster and Wyre referred. The project is providing multidisciplinary assessments, diagnosis and treatment planning, and its findings will inform the way we do this at a national level.

The proposed extension of the pilot project includes setting up a third site and an independent evaluation of the pilot, because we should not be marking our own homework. That should give us the evidence we need to determine whether a nationally commissioned service could be implemented across England. This approach balances the need to improve support for affected individuals and families with the requirement to ensure that any future national service is evidence-based, clinically effective and financially sustainable.

[Bob Blackman]

It is good news that the Minister is considering a national proposal. Will she undertake to have a meeting with the long-suffering victims of this scandal, who have been caring for their children for many years without support, in such desperate times, to show her commitment to doing what needs to be done for them? I think she will learn quite a lot from such a meeting.

[Dame Diana Johnson]

Of course I will. I would be very interested in doing that and learning more, and I am sure my office will be in touch with the hon. Gentleman about that.

Secondly, on research and development, we are working with clinicians from the pilot and other experts to see how we can improve the services available to affected patients.

Finally, on prevention, NHS England and the Medicines and Healthcare products Regulatory Agency have introduced strict measures to minimise valproate exposure during pregnancy, including pregnancy prevention programmes, and prescribing controls and specialist counselling for women who may become pregnant while taking the medication.

Let me close by again paying tribute to all the families whose lives have been changed forever by sodium valproate and the other issues that were set out in the Hughes report around pelvic mesh. I hope I have made clear how determined we are to respond to the Hughes report with the urgency and the compassion that those families absolutely deserve.